1. Home
  2. DMK


DMK Pharmaceuticals Corporation

Logo DMK Pharmaceuticals Corporation

Health Care

Biotechnology: Pharmaceutical Preparations



DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

Founded: 2006 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 5.2M IPO Year: N/A
Target Price: $1.50 AVG Volume (30 days): 11.0
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -9.90 EPS Growth: N/A
52 Week Low/High: $0.18 - $21.70 Next Earning Date: 02-18-2024
Revenue: $3,619,689 Revenue Growth: 134.95%
Revenue Growth (this year): -68.8% Revenue Growth (next year): 215.90%

Share on Social Networks: